Table 1.
Characteristics according to fibrosis stage in HCV-infected patients (N = 191).
Table 2.
Distribution of HCV-infected patients in every single fibrosis stage (N = 191).
Table 3.
Serum markers (HA, PIIINP, TIMP-1) and ELF® values according to fibrosis stage in each 5-year time period.
Fig 1.
Diagnostic accuracy (AUROCs) of indirect (Forns, APRI, FIB-4) and direct (ELF) scores to identify significant fibrosis (F2-4).
Table 4.
Diagnostic accuracy (AUROCs, 95% CI) of indirect (Forns, APRI, FIB-4) and direct (ELF) scores (N = 191) to identify significant fibrosis in each 5-year time period.
Table 5.
Diagnostic accuracy (PPV, NPV, Se, Sp) of indirect (Forns, APRI, FIB-4) and direct (ELF) scores (N = 191) to identify significant fibrosis according to their previously validated cutoffs.
Fig 2.
Predictive capacity of the ELF® score to identify clinical events during follow-up usingcryopreserved samples according to HCV-antiviral treatment response (n = 191).
Data of number of events (E) and patients at risk (R) in every 3 years time period.